Payers are seeking more value-based information to better inform decision making in the evaluation of new orphan and ultra-orphan technologies. The challenge lies with the value of the new technology and who is judging that value. Rising costs of orphan and ultra-orphan technologies will have more impact on market access in the future, with increasing resistance to high prices.
Orphan and Ultra-Orphan Technologies
European and Australian Payer Perceptions (Meeting Abstract